Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression.

ABSTRACT:

Background

Sorafenib is a first-line treatment option for advanced hepatocellular carcinoma (HCC) patients; however, survival predictors upon progression have not been well characterized. In the present study, we aimed to show the efficacy of multidisciplinary therapy for patients who had failed to respond to sorafenib treatment.

Methods

Among 146 BCLC stage B or C HCC patients treated with sorafenib monotherapy between July 2009 and August 2014, the first radiological progression according to the modified RECIST was identified in 71 patients; factors predicting overall survival (OS) and survival postprogression (SPP) were analyzed in these patients.

Results

The median OS and SPP for patients who failed to respond to sorafenib treatment were 10.5 and 6.2 months, respe

SUBMITTER: Kondo M 

PROVIDER: S-EPMC5498900 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature